Drugs / Recombinant human tissue kallikrein
Recombinant human tissue kallikrein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02868996 | Sep 2016 → Mar 2017 | stroke disorder | DiaMedica Therapeutics Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human tissue kallikrein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02868996 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human tissue kallikrein” NCT02868996 ↗ |
| Route | Intravenous | “intravenous dosing” NCT02868996 ↗ |